# Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping

Study · id `cardio:ct-nct01174693` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01174693](<https://clinicaltrials.gov/study/NCT01174693>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01174693

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 795 participants.

## Technical summary

Registry record NCT01174693. Randomized; no masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2014-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 795 participants (enrolled count; ClinicalTrials.gov record NCT01174693, source copy `cardio:ctgov-nct01174693-2015-03-17`, retrieved 2026-10-26)
- Start date: 2010-03 (registry gives no type) (ClinicalTrials.gov record NCT01174693, source copy `cardio:ctgov-nct01174693-2015-03-17`, retrieved 2026-10-26)
- Primary completion: 2014-12 (actual) (ClinicalTrials.gov record NCT01174693, source copy `cardio:ctgov-nct01174693-2015-03-17`, retrieved 2026-10-26)
- Completion: 2015-03 (actual) (ClinicalTrials.gov record NCT01174693, source copy `cardio:ctgov-nct01174693-2015-03-17`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01174693, source copy `cardio:ctgov-nct01174693-2015-03-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01174693-2015-03-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping
- Acronym: MAESTRO
- Condition: Cerebral Infarction
- Intervention (Drug): Triflusal
- Intervention (Drug): Clopidogrel
- Lead sponsor: Gangnam Severance Hospital
- Lead sponsor class: OTHER
- Collaborator: Myung In Pharmaceutical Company
- Collaborator class: UNKNOWN
- Collaborator: Yonsei University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry lists this organization as the lead sponsor: Gangnam Severance Hospital (`cardio:org-gangnam-severance-hospital`)
- Registry lists this organization as a collaborator: Yonsei University (`cardio:org-yonsei-university`)

## Provenance

Content hash: dbdbe190069cdcb20ca037498b3b61e220b5ed1af1286914f4691287244efdf8
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
